FCGR2A and neoplasm: However, it was recently shown that the Fc region contributes to the efficacy of anti-PD-L1 antibodies in the way that isotypes with higher affinity to activating FcγR mediate increased anti-tumor activity (13) providing us the rationale to investigate if glyco-engineering of anti-PD-L1 antibodies might result in further improvement.